A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders

Celgene Corporation6 enrolled

Overview

To investigate the safety of partially matched related human placental-derived stem cells (HPDSC) administered in conjunction with umbilical cord blood (UCB) stem cells from the same donor in subjects with various malignant or nonmalignant disorders potentially curable with stem cell transplantation and to assess potential restoration of normal hematopoiesis and immune function in subjects with these disorders

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hematologic Malignancies

Interventions

UCB and HPDSCPROCEDURE

single dose of UCB followed by one unit of HPDSC

Eligibility

Sex: ALLMax age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: * suitable UCB collected from partially or fully HLA matched related donor * subject requires umbilical cord transplantation Exclusion Criteria: * any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study * major anticipated illness or organ failure incompatible with survival from stem cell transplant

A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes